Long-acting version of Baxter’s hemophilia drug succeeds in study

Whatsapp News

Baxter's hemophilia drugBaxter International Inc said a potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.

The experimental drug, BAX 855, being tested as a preventive therapy and an -demand treatment in 138 previously treated adolescent and adult hemophilia A .

The trial’s main goal reduce bleeding rates compared with -demand treatment.

Hemophilia A, also called classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein.

in the twice-weekly prophylaxis, or preventive, arm of the trial experienced a 95 percent reduction in median yearly bleeding rates compared with those in the -demand arm, Baxter said.

The apply for U.S. marketing approval for the drug before the end of the year and said would begin another late-stage study test BAX 855 in previously treated under the age of 12.


Baxter raised the forecast for its hemophilia franchise in July, despite the potential for from Biogen Idec Inc’s long-acting treatment Eloctate, which the U.S. and Drug Administration approved in June.

BAX 855 is an extended-release version of Advate, which first approved a decade ago and is currently sold in 64 countries.

The experimental drug uses Nektar Therapeutics’ proprietary technology to extend the duration of activity of proteins in the body.

Deerfield, Illinois-based Baxter’s stock was about 1.2 percent on the Stock on . (Reuters)